Skip to main content

Table 2 Characteristics of ICU lengh stay and therapeutic strategy

From: Mucormycosis in intensive care unit: surgery is a major prognostic factor in patients with hematological malignancy

 Number of patients (%)Survivors (n = 21)Non-survivors (n = 53)P-value
Type of ICU0.11
 Medical, n (%)53 (71.6)13 (61.9)40 (75.5) 
 Surgical, n (%)13 (17.6)3 (14.3)10 (18.9) 
 Polyvalent, n (%)8 (10.8)5 (23.8)3 (5.7) 
Year of admission0.70
Antifungal treatment
 Treatment including L-AmB56 (75.7)19 (90.5)37 (69.8)0.08
 L-AmB alone, n (%)44 (59.5)14 (66.7)30 (56.6)0.60
 Association of L-AmB + other drug, n (%)12 (16.2)5 (23.8)7 (13.2)0.30
 Triazole drug alone, n (%)4 (5.4)1 (4.8)3 (5.7)1
 Echinocandine alone, n (%)1 (1.4)0 (0)1 (1.9)1
 None, n (%)13 (17.6)1 (4.8)12 (22.6)0.09
 Delay of efficient antifungal treatment, mean (SD)a9.5 (9.9)8.2 (7.6)10.1 (11.3)0.45
Interventions
 Surgical intervention, n (%)27 (36.5)12 (57.1)15 (28.3)0.03
 Cutaneous resection11 (14.9)3 (14.3)8 (15.1)1
 Lung resection7 (9.5)6 (28.6)1 (1.9)0.002
 Amputation2 (2.7)2 (9.5)00.08
 ENT resection4 (5.4)1 (4.8)3 (5.7)1
 Abdominal resection3 (4.1)03 (5.7)0.55
 Vasopressors, n (%)53 (71.6)9 (42.9)44 (83.0)0.001
 Mechanical ventilation, n (%)66 (89.2)14 (66.7)52 (98.1)< 0.001
 Renal replacement therapy, n (%)31 (41.9)5 (23.8)26 (49.1)0.07
  1. Italic values indicate significance of P-value (P < 0.05)
  2. L-AmB liposomal amphotericin B
  3. aResults are expressed as mean (SD) and compared with Student’s t test